ONC201, a dual inhibitor of Akt and ERK, is being evaluated in combination with paclitaxel for the treatment of platinum-resistant ovarian cancer in an ongoing phase II trial (NCT04055649). The gene discussed is AKT1; the disease is ovarian carcinoma.